These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16684603)

  • 41. Influence of comorbidities on the phenotype of patients affected by Charcot-Marie-Tooth neuropathy type 1A.
    Ursino G; Alberti MA; Grandis M; Reni L; Pareyson D; Bellone E; Gemelli C; Sabatelli M; Pisciotta C; Luigetti M; Santoro L; Massollo L; Schenone A
    Neuromuscul Disord; 2013 Nov; 23(11):902-6. PubMed ID: 23891256
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Charcot-Marie-Tooth disease type 1A: molecular mechanisms of gene dosage and point mutation underlying a common inherited peripheral neuropathy.
    Roa BB; Garcia CA; Lupski JR
    Int J Neurol; 1991-1992; 25-26():97-107. PubMed ID: 11980069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Charcot-Marie-Tooth disease].
    Lee YC; Chang MH; Lin KP
    Acta Neurol Taiwan; 2008 Sep; 17(3):203-13. PubMed ID: 18975529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gene dosage is a mechanism for Charcot-Marie-Tooth disease type 1A.
    Lupski JR; Wise CA; Kuwano A; Pentao L; Parke JT; Glaze DG; Ledbetter DH; Greenberg F; Patel PI
    Nat Genet; 1992 Apr; 1(1):29-33. PubMed ID: 1301995
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identical point mutations of PMP-22 in Trembler-J mouse and Charcot-Marie-Tooth disease type 1A.
    Valentijn LJ; Baas F; Wolterman RA; Hoogendijk JE; van den Bosch NH; Zorn I; Gabreëls-Festen AW; de Visser M; Bolhuis PA
    Nat Genet; 1992 Dec; 2(4):288-91. PubMed ID: 1303281
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration.
    Meyer zu Horste G; Miesbach TA; Muller JI; Fledrich R; Stassart RM; Kieseier BC; Coleman MP; Sereda MW
    Neurobiol Dis; 2011 Apr; 42(1):1-8. PubMed ID: 21168501
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New treatments for denervating diseases.
    Pleasure D
    J Child Neurol; 2005 Mar; 20(3):258-62. PubMed ID: 15832625
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy.
    Sociali G; Visigalli D; Prukop T; Cervellini I; Mannino E; Venturi C; Bruzzone S; Sereda MW; Schenone A
    Neurobiol Dis; 2016 Nov; 95():145-57. PubMed ID: 27431093
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Networking for new drugs.
    Ainsworth C
    Nat Med; 2011 Oct; 17(10):1166-8. PubMed ID: 21988973
    [No Abstract]   [Full Text] [Related]  

  • 50. [Molecular pathology of Charcot-Marie-Tooth disease type 1A: abnormal expression of PMP-22].
    Yoshikawa H; Nishimura T; Yanagihara T
    Rinsho Shinkeigaku; 1995 Dec; 35(12):1441-3. PubMed ID: 8752424
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 144th ENMC International Workshop: Outcome Measures in McArdle Disease, 29 September-1 November 2006, Naarden, The Netherlands.
    Quinlivan R; Vissing J
    Neuromuscul Disord; 2007 Jun; 17(6):494-8. PubMed ID: 17490880
    [No Abstract]   [Full Text] [Related]  

  • 52. Electromyographic tendon reflex recording: An accurate and comfortable method for diagnosis of charcot-marie-tooth disease type 1a.
    García A; Pelayo-Negro AL; Álvarez-Paradelo S; Antolín FM; Berciano J
    Muscle Nerve; 2015 Jul; 52(1):39-44. PubMed ID: 25363904
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neurophysiology and molecular genetics of Charcot-Marie-Tooth type 1 neuropathy in Croatian children: follow-up study.
    Barisić N; Mihatov I
    Croat Med J; 2000 Sep; 41(3):306-13. PubMed ID: 10962051
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized trial of botulinum toxin to prevent pes cavus progression in pediatric Charcot-Marie-Tooth disease type 1A.
    Burns J; Scheinberg A; Ryan MM; Rose KJ; Ouvrier RA
    Muscle Nerve; 2010 Aug; 42(2):262-7. PubMed ID: 20544937
    [TBL] [Abstract][Full Text] [Related]  

  • 55. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients.
    Sahenk Z; Nagaraja HN; McCracken BS; King WM; Freimer ML; Cedarbaum JM; Mendell JR
    Neurology; 2005 Sep; 65(5):681-9. PubMed ID: 16157899
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent advances in Charcot-Marie-Tooth disease.
    Baets J; De Jonghe P; Timmerman V
    Curr Opin Neurol; 2014 Oct; 27(5):532-40. PubMed ID: 25110935
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peripheral myelin protein-22 expression in Charcot-Marie-Tooth disease type 1a sural nerve biopsies.
    Hanemann CO; Stoll G; D'Urso D; Fricke W; Martin JJ; Van Broeckhoven C; Mancardi GL; Bartke I; Müller HW
    J Neurosci Res; 1994 Apr; 37(5):654-9. PubMed ID: 8028042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differentiation of Human Tonsil-Derived Mesenchymal Stem Cells into Schwann-Like Cells Improves Neuromuscular Function in a Mouse Model of Charcot-Marie-Tooth Disease Type 1A.
    Park S; Jung N; Myung S; Choi Y; Chung KW; Choi BO; Jung SC
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30110925
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phenotype and clinical evolution of Charcot-Marie-Tooth disease type 1A duplication.
    Berciano J; García A; Gallardo E; Ramón C; Combarros O
    Adv Exp Med Biol; 2009; 652():183-200. PubMed ID: 20225026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factors associated with foot and ankle strength in healthy preschool-age children and age-matched cases of Charcot-Marie-Tooth disease type 1A.
    Rose KJ; Burns J; North KN
    J Child Neurol; 2010 Apr; 25(4):463-8. PubMed ID: 19671887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.